Evidence map›Paper›PMID 23515281›Full record

Trial reportJournal of lipid research2013

A novel JNK2/SREBP-1c pathway involved in insulin-induced fatty acid synthesis in human adipocytes.

Minoru Ito, Michiaki Nagasawa, Naoki Omae, Masaki Tsunoda, Junichi Ishiyama, Tomohiro Ide, Yunike Akasaka, Koji Murakami

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Frontiers in nutrition · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Cannabidiol promotes browning in 3T3-L1 adipocytes.Molecular and cellular biochemistry · 2016
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Minoru ItoDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Michiaki NagasawaDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan. Electronic address: michiaki.nagasawa@mb.kyorin-pharm.co.jp.
Naoki OmaeDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Masaki TsunodaDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Junichi IshiyamaDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Tomohiro IdeDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Yunike AkasakaDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Koji MurakamiDiscovery Research Laboratories, Kyorin Pharmaceutical Company Limited, Tochigi 329-0114, Japan.
Kyorin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin plays important roles in apoptosis and lipid droplet (LD) formation, and it is one of the determinants involved in increasing fat mass. However, the mechanisms underlying insulin-induced enlargement of fat mass remain unclear. Our previous study suggested that insulin-induced increases in LDs are related to c-Jun N-terminal kinase (JNK)2-mediated upregulation of cell death-inducing DNA fragmentation factor-α-like effector (CIDE)C in human adipocytes. However, other genes involved in insulin/JNK2-induced LD formation are unknown. Here, we explored insulin/JNK2-regulated genes to clarify the mechanism of enlargement of LDs. Microarray analysis revealed that an insulin/JNK2 pathway mostly regulates expression of genes involved in lipid metabolism, including sterol regulatory element binding protein (SREBP)-1, a key transcription factor of lipogenesis. The JNK inhibitor SP600125 blocked insulin-induced upregulation of SREBP-1c expression. Small interfering RNA-mediated depletion of JNK2 suppressed insulin-induced nuclear accumulation of the active form of SREBP-1 protein and upregulation of SREBP-1c. Furthermore, depletion of JNK2 attenuated insulin-induced upregulation of SREBP-1c target lipogenic enzymes, leading to reduced de novo fatty acid synthesis. In addition, JNK2 coimmunoprecipitated with SREBP-1, reinforcing the correlation between JNK2 and SREBP-1. These results suggest that SREBP-1c is a novel insulin/JNK2-regulated gene and that the JNK2/SREBP-1c pathway mediates insulin-induced fatty acid synthesis, which may lead to enlargement of LDs in human adipocytes.

Indexed as

Active Transport, Cell NucleusAdipocytesAdultAnthracenesCell NucleusCells, CulturedFatty AcidsFemaleHumansHypoglycemic AgentsInsulinMaleMAP Kinase Signaling SystemMiddle AgedMitogen-Activated Protein Kinase 9Sterol Regulatory Element Binding Protein 1AnthracenesFatty AcidsHypoglycemic AgentsInsulinMitogen-Activated Protein Kinase 9pyrazolanthroneSREBF1 protein, humanSterol Regulatory Element Binding Protein 1cell death-inducing DNA fragmentation factor-α-like effectorc-Jun N-terminal kinase 2de novo lipogenesismicroarraysmall interfering RNAsterol regulatory element-binding protein-1c

Identifiers

PMID23515281
PMCPMC3646454
OpenAlexW2024103922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.